Table 5 Data characteristics in the primary studies
References | Study | Method (Study design) | Follow-up time | Disease definition | Participants, implant at baseline | Measurements | Pre-treatment | Treatment |
|---|---|---|---|---|---|---|---|---|
Carcuac et al. [48] | Surgical treatment of peri-implantitis: 3-year results from a randomized controlled clinical trial | RCT | 36 months | PD >  = 6 mm, BoP/SoP and marginal bone loss > 3 mm | Patients n: 100, Implants n: 179 | PD reduction, Radiographic bone level, BoP, Implant loss | Not mentioned | Pocket elimination using resective techniques |
Hallström et al. [47] | Open flap debridement of peri-implantitis with or without adjunctive systematic antibiotics: A randomized clinical trial | RCT | 12 months | Peri-implant marginal bone loss ≥ 2 mm as determined from a comparison of the bone level 1 year following implant reconstruction with the bone level at screening, or ≥ 3 mm in depth as determined from peri-apical radiograph, in combination with probing depth ≥ 5 mm and with bleeding or suppuration on probing | Patients: n = 39, Implants: n = 39 | PD reduction, Radiographic bone level, microbial composition and load | Not mentioned | Removal of inflamed tissue and mechanical cleaning of the implant without any additional therapy |
References | Procedures in experimental group/sites | Procedures in control group/sites | Additional surface treatment | Antimicrobial treatment | Maintenance | Implant type | Patient characteristics (smokers, systemic diseases, other modification factors) | |
|---|---|---|---|---|---|---|---|---|
Carcuac et al. [48] | Group 1 and 2: systemic antibiotics (amoxicillin 2 × 750 mg daily) | Group 3 and 4: No other treatment | Group 1 and 3: mechanical implant surface decontamination supplemented by an antiseptic agent (0.2% chlorhexidine gluconate) Group 2 and 4: mechanical implant surface decontamination with saline | Not mentioned | First year every 3 months, after that by referring dentist. Control at 12 and 36 months | Nobel Biocare (turned): 43 Nobel Biocare (TiUn): 87 Astra Tech (TiO): 9, Astra Tech (OsseoSpeed): 24, Straumann (SLA): 13, Neoss(ProAct): 3 | Current smokers: 33% (33) History of periodontitis 84% (84), Diabetes 5% (5) | |
Hallström et al. [47] | Peri- treatment Zithromax 250 mg × 2 at the day of surgery, 250 mg × 1 per day during four additional days | No other treatment | Cotton gauze in saline and cleaning with sterile curettes | Chlorhexidine 0.2% × 2 daily both groups | Every 3 months | Brånemark (t:5 c:11), Astra Tech (t:7 c:5), Straumann (t:7 c:3, Cresco (t:1) | Smoking history: 36.7% (14) of the participants, current: 30.7% (12) (t 40% (8) c 21% (4)) | |